Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering.
The company is developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). Alopexx's most advanced candidate, F598, has completed Phase 1 and pilot Phase 2 trials and was well tolerated, with a single infusion providing sustained serum levels for 2-3 months. The company's other lead candidate AV0328, a synthetic PNAG vaccine, completed a Phase 1 trial and was found to induce antibodies capable of killing a wide range of PNAG-expressing pathogens. Alopexx believes utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation.
The Cambridge, MA-based company was founded in 2006 and plans to list on the Nasdaq but has not selected a ticker yet (RC ticker: ALPX.RC). ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
